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Abstract
BACKGROUND: Neuroendocrine neoplasms of the pancreas (p-NEN) are common gastro-entero-pancreatic neuroendocrine 
neoplasms (GEP-NENs). The aim of this retrospective study was to review the value of Somatostatin Receptor Scintigraphy 
(SRS) in initial detection of p-NEN, evaluation of tumour extent and as imaging follow-up after radical surgery in patients with 
confirmed well (NETG1) or moderately (NETG2) differentiated p-NEN based on pathological WHO 2017 classification.
MATERIAL AND METHODS: Overall 281 patients with confirmed p-NEN were enrolled. The SRS was performed to evaluate 
primary p-NEN, to assess clinical stage of disease, based on current World Health Organization (WHO) classification and during 
clinical follow-up. A total of 829 examinations were performed over time in these 281 patients using 99mTc HYNICTOC. Images 
were acquired between 1–3 h after i.v. injection of radiotracer. Initially whole body WB-SPECT and then WB-SPECT/CT with 
standard iterative reconstruction were used.
RESULTS: There were 159 patients with NETG1 (57%) and 122 subjects with NETG2 (43%). The female to male ratio was 1.1:1. 
In 68 patients (22%) with NETG1/G2 eighty-seven SRSs (10%) were performed to confirm initial diagnosis. SRS results were as 
follow: true positive (TP) = 84 (97%), false negative (FN) = 3 (3%), no true negative (TN) or false positive (FP) results of SRS 
examination (sensitivity of SRS per patient was 96%). In 198 subjects (66%) SRS was used in evaluation and re-evaluation of 
the clinical stage. A total of 661 (80%) examinations were carried out in these patients. There were TP = 514 (77%), TN = 136 
(21%), FN = 7 (1%) and FP = 4 (1%) results. The sensitivity and specificity per patient were: 96% and 95%. The sensitivity and 
specificity per study were: 98% and 97%. In 35 patients (12%) SRS was used as imaging follow-up after radical surgery; there 
were overall 81 examinations (10%) performed. There were 76 (91%) TN results of SRS examinations and in 4 patients we 
identified recurrence (TP). In total, which consists of initial diagnosis/staging and patient follow-up, the sensitivity of SRS was 
96% and specificity 97% per patient and per study sensitivity and specificity was 98%.
CONCLUSIONS: SRS using 99mTc HYNICTOC acquired in WB-SPECT or WB-SPECT/CT techniques is an excellent imaging 
modality in detection of primary NETG1/G2 p-NEN. Our study confirms that SRS has high sensitivity and specificity, as a result 
has tremendous value as an examination method to assess clinical stage of disease and as an imaging follow-up after radical 
treatment.
KEY words: neuroendocrine neoplasms of the pancreas, p-NENs, gastro-entero-pancreatic neuroendocrine 
neoplasms, GEP-NENs, Somatostatin Receptor Scintigraphy, SRS
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Neuroendocrine neoplasms (NENs) are a relatively rare, 
heterogeneous group of various neoplasms which develop from 
highly specialized neuroendocrine cells located in the entire 
body. Gastro-entero-pancreatic neuroendocrine neoplasms/tu-
mours (GEP-NENs/NETs) comprise about 70% of all NENs, and 
about 2% of all neoplasms of the digestive system [1–3].
Neuroendocrine neoplasms of the pancreas (p-NEN) 
are common gastro-entero-pancreatic neuroendocrine neo-
plasms (GEP-NENs), which are clinically and functionally hetero-
geneous [4, 5]. Those tumours derive from the diffuse endocrine 
system (DES) cells which exist in the gastro-intestinal tract and in 
the pancreas [3]. According to the latest analysis of the Surveil-
lance, Epidemiology, and End Results (SEER) database an annual 
incidence of p-NEN is 0.48 per 100,000 population and appears to 
be increasing in the new millennium, probably as a consequence 
of using high quality imaging techniques which lead to better and 
earlier detection of p-NEN [6, 7].
Pancreatic NENs can be functional and non-functional tu-
mours. This classification of p-NENs is based on the presence or 
absence of clinical symptoms caused by hormonal over-secretion. 
It has been reported that 60–90% of p-NENs are non-functional 
(depending on which database is used) and as a result of their 
clinical silence they are usually diagnosed at more advanced clinical 
stages (CS) than those which present with a hormonal syndrome. 
In the case of metastatic disease at the time of initial diagnosis the 
possibility of a curative resection is limited, but still be considered 
even advanced disease [4, 5, 8].
The majority of p-NENs occur sporadically, as non-inherited 
tumours. However, a significant minority are associated with genetic 
syndromes such as multiple endocrine neoplasia type 1 (MEN1), 
von Hippel Lindau disease (VHL), von Recklinghausen’s syn-
drome (neurofibromatosis 1), and tuberous sclerosis. Of those 
tumours which produce detectable hormones multiple insulino-
mas are less than 5%, gastrinomas from 20% up to 30% are associ-
ated with MEN1. In comparison to gastrinomas, glucagonomas and 
somatostatinomas, well-differentiated insulinomas show benign 
clinical behaviour and have a notably good prognosis in most of 
cases. More malignant insulinoma is seen in approximately 10% 
of cases [4, 5, 9, 10].
The majority of NENs have specific tissue characteristics which 
include expression of somatostatin receptors (SSTR). Numer-
ous pNENs, including non-functional tumours except insulinomas, 
have high-level expression of SSTR among which SSTR subtype 
2 is mainly expressed by b-cells with a slightly lower expression of 
SSTR5 mostly by b-cells [4, 7]. 
This means that p-NENs can be targeted by molecular imag-
ing using somatostatin receptor imagining (SRI) and, as a result, 
SRS using 99mTc HYNICTOC has positive uptake for visualizing 
p-NENs [4, 5, 11–13].
When looking at the prognosis of any p-NEN, the histopatho-
logical grade (G) is vital. This grading divides NENs into three 
groups: tumours of low (G1), moderate (G2), and high (G3) 
malignancy. The criteria for the assessment of the “G” grading 
were firstly specified by European Neuroendocrine Tumour Soci-
ety (ENETS) in 2006 [14] and then were supported by the World 
Health Organization (WHO). Currently the new pathological clas-
sification of NETG1 and NETG2 is used based on UICC/AJCC, 
which is a new version of previous one based on ENETS/WHO 
classification from 2010 [15]. The new classification of NENs, 
including p-NENs is presented in Table 1. Histological malignancy 
grading was based on two criteria, the first was number of mitotic 
figures and the second was Ki-67 proliferation index determined 
by immunohistochemical analysis of expression of MIB1 antibody 
provided in percentages. If there were differences using both 
criteria, Ki-67 was used as a preferential one [16]. According to 
the above classification, two main categories of GEP-NENs were 
distinguished. The first group includes well-differentiated neo-
plasms NETG1 and NETG2 with Ki-67 below 20%; the second 
group consists of poorly-differentiated NET G3 or neuroendocrine 
carcinomas (NEC) with Ki-67 above 20%.
Various imaging techniques such as computed tomography 
(CT), magnetic resonance imaging (MRI), ultrasonography (US), 
endoscopic ultrasonography (EUS), positron emission tomography 
(PET) and somatostatin receptor scintigraphy (SRS) are performed 
to localize primary pNENs, assess clinical stage (CS) of disease 
and also as imaging follow-up.
The following factors including: initial histological grade of 
p-NEN cells, secretion and presence of local and distant metasta-
ses are important in evaluation of clinical stage of disease and help 
multidisciplinary team (MDT) to plan further treatment of p-NEN [4].
Aim of the study
The aim of this retrospective study was to evaluate whether 
Somatostatin Receptor Scintigraphy (SRS) using whole body (WB) 
SPECT or WB-SPECT/CT techniques are effective tools in initial 
detection of p-NEN, evaluation of tumour extent and alters clini-
cal management during clinical follow-up after radical surgery in 
Table 1. Proposed NEN classification according to AJCC/UICC and WHO 2017
NEUROENDOCRINE NEOPLASMS, NEN 
Ki-67 < 20% Ki-67 > 20%
NET G1 NET G2 NET G3 NEC
Well-differentiated tumours Neuroendocrine cancers 
Ki-67 < 3% Ki-67
from 3% to 20%
Ki-67 > 20%, usually between 21% 
a 55%
Ki-67 > 21%, usually > 55%
— large-cell cancers  
— small-cell cancers 
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patients with well (NETG1) or moderate (NETG2) differentiated 
p-NEN confirmed by pathology.
Material and methods
The protocol for this retrospective study was accepted by the 
institutional ethics committee. A total of 281 patients with confirmed 
neuroendocrine neoplasms of the pancreas were included. There 
were 148 females and 133 males (ratio 1.11:1). In all cases a pa-
thologist specialized in NEN reported and verified the histology 
results, in each case. The histopathology reports comprised 
histological grade and the stage of the neuroendocrine neoplasm 
(TNM) according to AJCC/UICC 2017 classification. Patients and 
tumour characteristics are presented in Table 2.
In all subjects, diagnosis, treatment and further diagnostic/im-
aging approaches were discussed within a multidisciplinary team 
(MDT).
Somatostatin receptor scintigraphy (SRS) was performed to 
evaluate primary p-NEN, to assess clinical stage of disease, based 
on current AJCC/UICC classification, and during clinical follow-up. 
Overall 829 SRS examinations were performed. 
In each case 550-740MBq of 99mTc HYNICTOC (Tektrotyd®; 
National Centre for Nuclear Research — Polatom, PL) was used. 
The detailed method of kit labelling with 99mTc has been described 
previously [17, 18]. Briefly, the peptide conjugates [HYNIC, Tyr3] 
octreotide was synthesized by standard F-moc solid-phase syn-
thesis [19] and used for kits manufacturing under aseptic condi-
tions. The labelling yield exceeded 90% in all cases with the free 
pertechnetate content in the range of 3.63 ± 1.67% (TLC). 
SRS images were acquired between 1 and 3 h after i.v. injec-
tion of radiotracer. Initially SRS was performed using a whole-body 
(WB) SPECT (Single Photon Emission Computed Tomography) 
method using Symbia-E gamma camera (Siemens Healthcare, 
IL; USA). Reconstruction algorithms were based on the ordered 
subset expectation maximization (OSEM), iterative reconstruction 
software (3D flash) on e-soft workstation. In each case using 
30 iteration and 16 subsets, with standard Gaussian filter 9.0, 
recommended by manufacturer. In each case 128 x 128 matrix 
with approximately 64 projections (20 seconds per projection) 
over an 360º rotation were utilized, there was no attenuation 
correction (non AC). 
Then SRS was performed using Discovery 670 Pro SPECT/CT 
system (GE Healthcare, WI, USA), based on WB-SPECT/CT method 
of examination. SPECT data was acquired using 128 x 128 matrix 
with approximately 60 projections (25 seconds per projection) 
over an 360º rotation. Computed tomography (CT) was performed 
without i.v. contrast enhancement. Reconstruction algorithms were 
based on iterative reconstruction algorithm: Evolution — OSEM 
Table 2. Patients and tumour characteristics in well (G1) and moderate (G2) differentiated pNENs
ALL, n = 281 NETG1, n = 159 NETG2, n = 122
Female to male ratio 1.11 1.01 1.26
Mean age (range) in initial diagnosis 54.86 (17-87) 55.23 (17-86) 54.29 (20-87)
Size of the tumour (pathology) mean (SD), mm 33.88 ( ± 26.22) 27.34 ± 23.62 43.21 ± 28.84
Ki-67 (mean, standard deviation) 4.17 ± 4.60 1.39 ± 1.28 7.89 ± 5.33
pT (initial), n = 281 n = 281 n = 159 n = 122
pT1 (%) 73 (26) 65 (41) 8 (7)
pT2 (%) 71 (25) 48 (30) 23 (19)
pT3 (%) 61 (22) 16 (10) 45 (37)
pT4 (%) 40 (14) 9 (6) 31 (25) 
pTx or no data (%) 36 (13) 21 (13) 15 (12)
N base on surgery, n = 281 n = 281 n = 159 n = 122
N0 (%) 126 (45) 95 (60) 31 (25)
N1 (%) 122 (43) 37 (23) 85 (70)
Nx or no data (%) 33 (12) 27 (17) 6 (5)
M base on surgery/follow-up/imaging, n = 281 n = 281 n = 159 n = 122
M0 (%) 139 (49) 97 (61) 42 (34)
M1 (%) 102 (36) 32 (20) 70 (57)
Mx or no data (%) 40 (14) 30 (19) 10 (8) 
CS (initial), n = 281 n = 281 n = 159 n = 122
I — IIIa — local (%) 145 (52) 115 (72) 30 (25)
IIIb — regional (%) 33 (12) 13 (8) 20 (16)
IV — distal (%) 103 (37) 31 (19) 72 (59)
Metastases
Liver (%) 97 (35) 26 (16) 71 (58)
Bones (%) 13 (5) 4 (3) 9 (7)
Lungs (%) 5 (2) 2 (1) 3 (2)
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(with resolution recovery) including 4 iterations and 10 subsets with 
standard Gaussian filter using in each case a Xeleris workstation.
Each SRS was defined as pathological if any focal or diffuse 
non-physiological accumulation was recognized during examina-
tion. Diffuse low-activity intestinal uptake on SRS was defined 
as non-specific, physiologic bowel uptake. Lesions were assessed 
due to their intensity of accumulation using the Krenning scale, 
similar to the standard SRS using Octreoscan™ evaluation. In 
each case, the Krenning extension of disease was used to classify 
the extension of the tumour, both methods have been described 
previously [18–20]. 
SRS was read by two specialists in nuclear medicine and 
was interpreted as true positive (TP) when the patient had histo-
logically confirmed p-NEN and there were at least Krenning 2 focal 
pathologically high uptake of radiotracer. True negative (TN) result 
was associated with no focal uptake of radiotracer on SRS and 
no evidence of the presence of disease during at least 12-month 
follow-up, clinically and on other imaging techniques, including 
endoscopic ultrasound (EUS), CT and magnetic resonance imaging 
(MRI) before and after i.v. contrast administration. A false positive 
(FP) was reported when there was focal high uptake on SRS (at least 
Krenning 2), but there was no evidence of p-NEN on other imaging 
techniques, clinically and during clinical and imaging follow-up. 
A false negative (FN) study was defined when there was confirm-
able tumour (p-NEN) which was not seen in SRS.
Histological and clinical information including assessment of 
tumour type based on ACJJ/UICC 2017 classification, including 
Ki-67 and the initial clinical stage (CS) of disease were available 
for analysis. 
Statistical analysis
The standard statistics using sensitivity, specificity PPV and NPV 
were used based on pathology reports as gold standard. If no speci-
men of tumour was available, clinical, biochemical and structural 
imaging were used to assess final results of examination. In case 
of negative SRS study and presence of any suspected lesions, 
patients were evaluated based on clinical follow-up. Differences be-
tween groups were assessed using non-parametric Mann-Whitney 
U test. In each case P < 0.05 was defined as significant. 
Results
There were 159 subjects with NETG1 (57%) and 122 sub-
jects with NETG2 (43%). In patients with NETG1 the mean age 
was 55.23 years (range 17–86) and in subjects with NETG2 the 
mean age was 54.29 (range 20–87). The mean size of the tumour 
(based on histopathology) were as follows: in NETG1 — 27.34 mm 
(SD ± 23.62), in NETG2 — 43.21 mm (SD ± 28.84). The mean Ki-67 
proliferation index was 1.39 % (SD ± 1.28) in patients with NETG1 
and 7.89 % (SD ± 5.33) in those with NETG2. In 54 cases there were 
no data regarding Ki-67 index and in 103 subjects no information 
about size of the tumours was available in histopathology reports; 
in those patients tumour size evaluation was based on structural 
imaging CT/MRI or EUS.
The image quality of SRS using 99mTc HYNICTOC was deter-
mined by both readers (JRB & JBC) to be excellent or very good; 
in the cases with small tumours the visualization was difficult but 
still clear enough to make a diagnosis of p-NET.
The analysis shows that tumours of pT1 and pT2 were usually 
identified in subjects with NETG1. We detected pT1 tumours in 65 
cases with NETG1 (41%) and only 8 with NETG2 (7%) (P < 0.05), 
pT2 in 48 subjects with NETG1 (30%) and in 23 with NETG2 (19%) 
(P > 0.05). In comparison, pT3 and pT4 tumours most frequently 
occurred in patients with NETG2. We noted pT3 tumours in 45 
cases with NETG2 (37%) and in 16 with NETG1 (10%), pT4 in 
31 subjects with NETG2 (25%) and in 9 with NETG1 (6%) (Table 2). 
The analysis of regional lymph nodes metastasis in patients af-
ter surgical treatment revealed no lymph nodes involvement in 126 
cases, including 95 with NETG1 (60%) and 31 with NETG2 (25%). 
There were 122 subjects with metastasis in a single regional lymph 
(N1), in 37 patients with NETG1 (23%) and in 85 with NETG2 (70%). 
There were 33 (12%) patients in whom regional lymph nodes could 
not be assessed (Table 2). 
Distant metastasis (M) were noted in 102 patients, in 32 
with NETG1 (20%) and in 70 with NETG2 (57%). There were 139 
cases with no evidence for metastases. In 40 subjects metasta-
ses could not be assessed. There were 97 (35%) patients with 
metastasis to the liver, including 71 with NETG2 (58%) and 26 with 
NETG1 (16%). Thirteen subjects (5%) had bone metastases and in 
5 (2%) patients we detected lung metastasis (Table 2). 
The assessment of clinical stage (CS) revealed that there were 
145 patients (52%) with I-IIIa CS, 115 with NETG1 (72%) and 30 with 
NETG2 (25%). In 33 cases (12%) we noted IIIb CS, in 13 with NETG1 
(8%) and in 20 with NETG2 (16%). There were 103 subjects (37%) 
with IV CS, which included 72 (59%) patients with NETG2 and rest 
with NETG1 (19%) (Table 2).
In 68 patients (22%) SRS was used to confirm the initial diag-
nosis and 87 (10%) SRS were carried out. In this group of patients, 
the results were as follows: true positive (TP) = 84 (97%), false 
negative (FN) = 3 (3%), no true negative (TN) or false positive (FP) 
results of SRS examination (sensitivity of SRS per patient was 96%). 
In 198 subjects (66%) SRS was used in evaluation of the clinical 
stage and overall 661 (80%) examination were performed. The fol-
lowing results were obtained: TP = 514 (77%), TN = 136 (21%), 
FN = 7 (1%) and FP = 4 (1%). 
The sensitivity and specificity per patient were: 96% and 95%. 
The sensitivity and specificity per study were 98% and 97%. In 35 
patients (12%) SRS was used as imaging follow-up after radical 
surgery; a total of 81 examinations (10%) were carried out. There 
were 76 (91%) TN results of SRS and in 4 patients we identified 
recurrence (TP). In total, which consists of initial diagnosis/stag-
ing and follow-up, the sensitivity was 96% and specificity 97% per 
patient and per study sensitivity and specificity was 98%. Summa-
rized SRS results in all groups of patients are presented in Table 3.
Discussion
As a consequence of recent advances in imaging technology 
and having better knowledge of p-NENs, the diagnosis and treat-
ment approaches of asymptomatic and symptomatic pNENs have 
improved. Various structural imaging such as CT, MRI and endo-
scopic ultrasound (EUS), as well as functional techniques such 
as somatostatin receptor imaging are currently utilized to localize 
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the primary tumour, assess clinical stage (CS) of disease and also 
as follow-up imaging after radical surgery [2–5]. 
CT and MRI have a relatively low sensitivity in detecting of 
low volume disease or multifocality of disease, both of which are 
common in patients with MEN1 syndrome associated with pNENs. 
Whilst EUS, which is currently the best method for detection of any 
focal pancreatic lesions, has a better resolution and sensitivity, it 
has a limited field of view. It provides very good visualization of the 
head and body of the pancreas, but the distal part of the pancreatic 
tail could be problematic in detection of small tumours. Local clini-
cal staging only can be achieved using EUS; therefore, it should 
be combined with other tests. 
In the last 2 decades it has been found that functional imaging 
of p-NEN plays a key role in evaluation of patients with suspected 
or confirmed NEN. Numerous studies have demonstrated that the 
current significance of somatostatin receptor imaging, including 
SRS, especially using SPECT/CT or PET/CT [4, 17–24]. In our 
data sets we indicated high accuracy of both the WB-SPECT 
or WB-SPECT/CT techniques in detection of active disease in 
patients with p-NEN. To our knowledge, it is the largest series of 
patients with confirmed NETG1 and NETG2 p-NENs, based on new 
classification ACJJ/UICC. It has been our standard clinical practice 
to perform SRS (WB-SPECT/CT) using 99mTc HYNICTOC as the main 
imaging technique used for detection of primary p-NENs, staging 
of disease and in subjects who had previously undergone radical 
surgery. This approach has been explored by our team for at least 
previous 14 years [25–27].
Various studies indicated that PET/CT with 68Ga labelled 
somatostatin analogues is immensely sensitive and has a high 
specificity for localizing p-NENs [4, 28–29]. Generally, when per-
forming PET/CT using 68Ga SST analogues in greater number of 
studies for p-NENs, the sensitivity varies from 86% up to 100% and 
the specificity from 79% up to 100% and is superior to MRI with DWI 
[30]. But this technique has a limitation which is the detection of 
insulinomas — the sensitivity decreases to 25% [31]. In addition, 
access to PET/CT and the 68Ga analogues may be limited.
Most comparative studies used planar 111In pentetreotide and 
compare to tomographic 68Ga PET/CT, which is methodologically 
incorrect, because these studies do not compare like with like. Only 
a few reports compare SRS using 99Tc HYNICTOC vs. 68Ga DOTA-
TOC/TATE/NOC. In all these studies SPECT was compared to PET, 
but SPECT was not performed using current state-of-the-art imaging 
techniques such as iterative reconstruction and WB-SPECT/CT at-
tenuation correction reconstruction technique, except single recent 
study which indicated clinical decision change in the one third of 
cases [32]. However, the authors did not use optimized reconstruc-
tion methods with the SPECT/CT. 
Compared to previously published studies using 68Ga DOTA-
TOC/TATE PET/CT the results of our study, showing a sensitivity 
and specificity which was always equal or greater than 95% in all 
group of patients with confirmed p-NETs, shows that, if optimized, 
the SPECT/CT-based agents compare well with PET. This is par-
ticularly true in our study because we have the results of a large 
number of studies performed in in a large cohort of pNET patients. 
This clearly indicated the high level of accuracy of SRS using 99mTc 
HYNICTOC in this patient group. However, the high prevalence of 
disease means we can be more certain of the sensitivity than the 
specificity. 
The approach described in our study using 99mTc HYNICTOC 
is also cheaper than using PET/CT and can be performed on 
any working day in most Nuclear Medicine departments. Thus, 
this technology seems to have a practical advantage compared 
to quite complicated and expensive PET/CT using 68Ga SST 
analogues The authors acknowledge that although 68Ga DOTA-
TOC/TATE PET/CT is currently is the best functional methods in 
detection p-NEN, its utility is restricted not just by cost but the 
need to access a PET/CT scanner and the current shortage of the 
required gallium/germanium generators.
The results of our study show that SRS with 99mTc HYNICTOC 
using the best in SPECT/CT is a highly sensitive and specific imag-
ing technique. According to our results, the high sensitivity of the 
test per patient was noted in the group of subjects in whom SRS 
Table 3. Results of Somatostatin Receptor Scintigraphy examinations in diagnosis group, staging group and follow-up group
Results of SRS SRS studies Diagnosis group, n = 68 Staging group, n = 198 Follow-up group, n = 35
NET G1 NET G2 NET G1 NET G2 NET G1 NET G2
TP 602 (73%) 69 (80%) 15 (17%) 216 (33%) 298 (45%) 0 4 (5%)
TN 212
(26%)




















All 829 (100%) 71 (82%) 16 (18%) 327 (49%) 334 (51%) 51 (63%) 30 (37%)
87 (10%) 661 (80%) 81 (10%)
  Diagnosis (n) Staging (n) Follow-up (n) All (%)
NETG1 54 92 13 159 (56.6)
NETG2 15 102 5 122 (43.4)
NETG3 0 0 0 0
SUMA 69 194 18 281
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was performed to assess initial diagnosis. As a consequence, 99mTc 
HYNICTOC SRS helped correctly identify those patients without the 
disease. Therefore, this method can be used to assess the localiza-
tion and extension of tumour when functional p-NENs are suspected 
but tumours cannot be detected on cross-sectional images such 
as CT or MRI. Our data also confirm that 99mTc HYNICTOC SRS 
is an appropriate tool in evaluation of clinical stage of disease and 
in follow-up of pNENs. 
A further advantage in using 99mTc HYNICTOC is the lower 
radiation exposure compared to standard 111In-pentetreotide 
(Octreoscam®). The agent is cleared rapidly from the blood; most 
of the activity is eliminated entirely through the kidneys (64% of the 
injected dose within 12 h). The effective dose is 0.005 mSv/MBq, 
which for a patient receiving the recommended maximum admin-
istered activity of 740 MBq is only 3.8 mSv [33].
This compares favourably to 111In-pentetreotide which is also 
cleared rapidly from the blood, with excretion almost entirely through 
the kidneys giving an effective dose is 0.054 mSv/MBq. For a pa-
tient recommended maximum administered activity of 222 MBq 
is 12 mSv, which is over 3 times higher than with 99mTc HYNICTOC 
[34]. The radiation dose in 70 kg patient from 68Ga-DOTATOC/TATE 
is approximately 2.9–3.2 mSv, which is similar to radiation dose of 
99mTc HYNICTOC [35, 36]. A modern CT used as part of the PET/CT 
or SPECT/CT will contribute an additional 2mSv to the total effec-
tive dose. [34].
Conclusions
The results from this study show the SRS using 99mTc HYNIC-
TOC acquired in WB-SPECT or WB-SPECT/CT techniques deliv-
ers high-accuracy results in the detection of primary well (NETG1) 
and moderate (NETG2) differentiated p-NEN. It is more widely 
available than 68Ga-DOTATOC/TATE PET but yields similar results at 
a lower cost. Furthermore, it is excellent method for the assessment 
of clinical stage of pNEN and in imaging follow-up in patients after 
radical surgery.
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